H Ilkova, B Glaser, A Tunckale, N Bagriacik, E … - Diabetes Care, 1997 - Am Diabetes Assoc OBJECTIVE: Type 2 diabetes is a slowly progressive disease, in which the gradual
deterioration of glucose tolerance is associated with the progressive decrease
in beta-cell function. Hyperglycemia per se has deleterious effects on both ... Cited by 264 - Related articles - BL Direct - All 6 versions
EA Ryan, S Imes, C Wallace - Diabetes care, 2004 - Am Diabetes Assoc OBJECTIVE—Type 2 diabetes is associated with defects in insulin secretion and
insulin action. Hyperglycemia may aggravate these defects, a feature known as
glucose toxicity. Previous studies have shown that acute correction of ... Cited by 136 - Related articles - BL Direct - All 9 versions
Y Li, W Xu, Z Liao, B Yao, X Chen, Z Huang, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Optimal glycemic control was achieved within 6.3 ± 3.9 days by CSII
in 126 patients. The remission rates (percentages maintaining near euglycemia)
at the third, sixth, twelfth, and twenty-fourth month were 72.6, 67.0, ... Cited by 120 - Related articles - BL Direct - All 8 versions
B Glaser, G Leibovich, R Nesher, S Hartling, … - Acta Endocrinologica, 1988 - eje.org Abstract. In Type II, non-insulin-dependent diabetes, insulin secretion is often
reduced to the point where oral hypoglycaemic agents fail to control the plasma
glucose level. We studied 12 patients (age 41–66 years; 4 lean, 8 obese) ... Cited by 62 - Related articles - All 8 versions
P Valensi, I Moura, M Le Magoarou, J Paries, G … - Diabetes & metabolism, 1997 - cat.inist.fr Le traitement des diabétiques non insulinodépendants(DNID) obèses en mauvais
équilibre glycémique malgré un traitement anti diabétique oral maximal est
difficile. Dans une série de 82 DNID en surpoids, nous avons étudié ... Cited by 40 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org M Alvarsson, G Sundkvist, I Lager, M … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—ß-Cell function, glycemic control, and quality of
life were monitored over 2 years in 39 patients with islet cell
antibody-negative type 2 diabetes diagnosed 0–2 years before inclusion in ... Cited by 90 - Related articles - BL Direct - All 8 versions
